Clinical Development of VE303, a Live Biotherapeutic Product (LBP) for Prevention of Recurrent C. difficile Infection and Treatment of Antibiotic-Induced Dysbiosis
Award Notice Posted
Not the latest version. See the latest special notice from .
- Solicitation number
- BAA-18-100-SOL-00003
- Agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Awarded
- to Vedanta Biosciences, Inc.
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75A50120C00177 Federal contract award
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Place of performance
- Boston MA 02116 USA
Notice details come from SAM.gov. Updated .
About this opportunity
This competitively awarded cost-share contract from the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response grants $76,943,067 to Vedanta Biosciences, Inc. for the clinical development of VE303, a live biotherapeutic product intended to prevent recurrent Clostridioides difficile infection and treat antibiotic-induced dysbiosis. The government's total cost share amount under the contract is $76,943,067, which was awarded on July 23, 2021 to Vedanta Biosciences, Inc. for the development of this therapeutic to address Clostridioides difficile infection and dysbiosis resulting from antibiotic use.
Notice text
This a competivitely awarded cost share contract. The Government's total cost share is $76,943,067.
Awarded contract 75A50120C00177 to VEDANTA BIOSCIENCES, INC. for 76943067.00 on 2020-09-28.
Notice history
7 notices listed here. See the rest on GovTribe.
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity